Hikma Pharmaceutical | HIK - Selling And Administration Expenses

Stock Price
1,619.00
Daily Change
-14.00 -0.86%
Monthly
3.25%
Yearly
-29.73%
Q1 Forecast
1,600.34

Hikma Pharmaceutical reported $139M in Selling and Administration Expenses for its fiscal semester ending in June of 2025.





Selling And Administration Expenses Change Date
argenx SE USD 336.29M 14.94M Sep/2025
AstraZeneca USD 4.61B 4.46B Dec/2025
Autolus Therapeutics Ltd USD 27.96M 1.58M Jun/2025
Bayer EUR 3.4B 140M Sep/2025
Fresenius EUR 676M 64M Sep/2025
Galapagos EUR 34.55M 3.88M Sep/2025
Genmab DKK 144M 18M Jun/2025
GlaxoSmithKline GBP 2.68B 518M Dec/2025
GRIFOLS EUR 284.99M 2.24M Sep/2025
Hikma Pharmaceutical USD 139M 149M Jun/2025
Merck EUR 1.46B 16M Sep/2025
Orion EUR 110.7M 26.1M Dec/2025
Recordati EUR 171.38M 15.6M Sep/2025
Roche Holding CHF 7.28B 3.99B Dec/2025
Sanofi EUR 2.75B 455M Dec/2025
UCB EUR 1.29B 221M Dec/2024